Market Intelligence, Clinical Progress, and High-Purity Reagents for Renal Cell Carcinoma and Solid Tumor Therapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for HAVCR1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | HAVCR1 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View HAVCR1 Products |
| Gene Delivery | HAVCR1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View HAVCR1 Products |
| Benchmark Ab | Anti-HAVCR1 (Sequence of CDX-014) Recombinant positive control. |
View HAVCR1 Products |
| Validator | HAVCR1 siRNA Set For knockdown verification. |
View HAVCR1 Products |
| Related Target A | HAVCR2 Synergistic immune checkpoint regulation in tumor microenvironments. |
View HAVCR2 Products |
| Related Target B | TIMD4 Subfamily homolog screening to avoid off-target toxicity. |
View TIMD4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Shedding Decoy Interference (Soluble KIM-1) | Recombinant soluble HAVCR1 proteins available with strict monomeric/oligomeric conformation verification by SEC-HPLC |
| Subfamily Off-target Screening (TIM-3/TIM-4) | Homolog panel proteins (HAVCR2, TIMD4) strictly verified by mass spectrometry |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live HAVCR1/CD365 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for HAVCR1 therapeutics is intensifying, with major players shifting focus from traditional mAbs to Antibody-Drug Conjugates (ADCs) and CAR-T therapies. As first-generation therapies reach the clinic, the next wave of R&D is targeting membrane-proximal epitopes to bypass the decoy effect of shed soluble HAVCR1 (sKIM-1) in circulation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Celldex Therapeutics, Eisai | Renal Cell Carcinoma (RCC), Ovarian Cancer | Internalization Assay (Need high-purity ECD-Fc) |
| CAR-T | Academic Institutions, Biotech Startups | Clear Cell Renal Cell Carcinoma (ccRCC) | Target Cell Line Construction (Need Lentivirus) |
| Bispecific Antibody | Invenra, Multi-targeting Developers | Solid Tumors, Immunotherapy combinations | Heterodimer Validation (Need Cross-reactive Abs) |